Sanofi SA (SNY) Stock AnalysisSNYStock AnalysisSanofi SA

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sanofi SA appears to be a good buy right now due to its attractive dividend yield of approximately 5.4%, which can rise to nearly 11% when factoring in stock buybacks, and a forward P/E ratio of 8.79, significantly lower than industry peers. The recent FDA approval of its on-body injector for isatuximab has boosted investor confidence, leading to a 6% rebound in August. However, the main risk is the stock's year-to-date decline of 7.07%, indicating potential volatility.

3 analysts cover SNY: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 79.36.